Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Dermatology Unit, Hospital de Baza, Granada, Spain.
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1492-1498. doi: 10.1111/jdv.14841. Epub 2018 Mar 30.
Psoriasis has been related to a large number of cardiovascular risk factors such as hypertension, diabetes mellitus and arteriosclerosis. The increased carotid intima-media thickness (IMT) could be considered to be a marker of generalized arteriosclerosis.
To assess the effect of systemic and biological drugs on psoriatic patients' carotid IMT.
A prospective study was performed. We studied 53 patients with moderate and severe psoriasis from our psoriasis dermatological unit, analysing lipid and glucose metabolism and performing a carotid IMT sonography before introduction of systemic and biological drugs. After that, we performed an 8-month closely analytic and sonographic follow-up.
The IMT of the patients with psoriasis treated with biological drugs tended to decrease, although this occurrence was not statistically significant (P = 0.086). The subgroup analysis revealed that patients treated with methotrexate (P = 0.045) and anti-IL-12/23 (P = 0.010) presented a decrease in their IMT levels. This analysis also showed a decrease in glycaemia and insulin levels in patients treated with TNF-alpha inhibitors and ustekinumab.
Our study suggests that the carotid IMT may benefit from treatment with biological drugs, particularly anti-IL-12/23 and methotrexate in patients suffering from moderate and severe psoriasis. However, larger longitudinal studies should be performed to fully confirm these results.
银屑病与许多心血管危险因素有关,如高血压、糖尿病和动脉硬化。颈动脉内膜中层厚度(IMT)增加可被认为是全身性动脉硬化的标志物。
评估全身和生物药物对银屑病患者颈动脉 IMT 的影响。
进行了一项前瞻性研究。我们研究了来自我们的银屑病皮肤科单位的 53 名中度和重度银屑病患者,分析了血脂和糖代谢,并在引入全身和生物药物之前进行了颈动脉 IMT 超声检查。之后,我们进行了 8 个月的密切分析和超声随访。
接受生物药物治疗的银屑病患者的 IMT 有下降的趋势,但这一变化没有统计学意义(P = 0.086)。亚组分析显示,接受甲氨蝶呤(P = 0.045)和抗 IL-12/23(P = 0.010)治疗的患者 IMT 水平下降。该分析还显示,接受 TNF-α 抑制剂和乌司奴单抗治疗的患者血糖和胰岛素水平降低。
我们的研究表明,颈动脉 IMT 可能受益于生物药物治疗,特别是抗 IL-12/23 和甲氨蝶呤治疗中重度银屑病患者。然而,需要进行更大的纵向研究来充分证实这些结果。